Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YARS1 | P54577 | 2/20 | 0.73 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30946748 | 0.91 | YARS1 (0.60) | YARS1SLC7A5CTSC | |
| SCHEMBL29697023 | 0.89 | YARS1 (0.60) | YARS1SLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL13200512 | 0.89 | YARS1 (0.59) | YARS1SLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL29615665 | 0.87 | OPRD1 (0.59) | YARS1SLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL29511618 | 0.82 | MME (0.67) | SLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL8695556 | 0.82 | MME (0.67) | SLC7A5OPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL29803603 | 0.82 | MME (0.67) | SLC7A5OPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL3037096 | 0.82 | MME (0.67) | SLC7A5OPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL4282059 | 0.82 | MME (0.67) | SLC7A5OPRD1OPRM1OPRK1 | |
| Phenylalanyltyrosine SCHEMBL31255162 | 0.82 | MME (0.67) | SLC7A5OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | YARS1 336/4885SLC7A5 657/4885OPRD1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.